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Abstract
Fetal membranes (FM) derived mesenchymal stromal/stem cells (MSCs) are higher in number, expansion and differentiation
abilities compared with those obtained from adult tissues, including bone marrow. Upon systemic administration, ex vivo
expanded FM-MSCs preferentially home to damaged tissues promoting regenerative processes through their unique
biological properties. These characteristics together with their immune-privileged nature and immune suppressive activity,
a low infection rate and young age of placenta compared to other sources of SCs make FM-MSCs an attractive target for
cell-based therapy and a valuable tool in regenerative medicine, currently being evaluated in clinical trials. In the present
study we investigated the permissivity of FM-MSCs to all members of the human Herpesviridae family, an issue which is
relevant to their purification, propagation, conservation and therapeutic use, as well as to their potential role in the vertical
transmission of viral agents to the fetus and to their potential viral vector-mediated genetic modification. We present here
evidence that FM-MSCs are fully permissive to infection with Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), Varicella
zoster virus (VZV), and Human Cytomegalovirus (HCMV), but not with Epstein-Barr virus (EBV), Human Herpesvirus-6, 7 and 8
(HHV-6, 7, 8) although these viruses are capable of entering FM-MSCs and transient, limited viral gene expression occurs.
Our findings therefore strongly suggest that FM-MSCs should be screened for the presence of herpesviruses before
xenotransplantation. In addition, they suggest that herpesviruses may be indicated as viral vectors for gene expression in
MSCs both in gene therapy applications and in the selective induction of differentiation.
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Introduction
Nonembryonic stem cells (SCs) opened new avenues in
developmental biology and regenerative medicine. Mesenchymal
stromal/cells (MSCs) [1] constitute a heterogeneous population
found first in bone marrow (BM) [2]. MSCs are easy to isolate [3],
they have a superior expansion potential as compared to other
adult tissue-derived SCs, and are endowed with low inherent
immunogenicity and the ability of modulating/suppressing
immunologic responses [4]. These characteristics together with
high plasticity, a tendency to migrate into damaged tissues where
they orchestrate regenerative processes, and their outstanding
record of safety in clinical trials make these cells prime candidates
for cellular therapy. Indeed MSCs from BM or umbilical cord
blood have been used in therapeutic approaches involving
hematopoietic, cardiovascular, central nervous, gastrointestinal,
renal, and orthopedic systems, as well as in the temptative
treatment of genetic disorders and cancer [4,5], and are being
considered for gene therapy [6,7].
Adult BM is the common source of MSCs for clinical use [5],
however the frequency of MSCs in human adult BM is relatively
low, and availability is conditional to invasive procedures. As a
consequence a quest for alternative sources of MSCs was initiated,
resulting in finding MSCs in multiple adult and neonatal tissues
like fat, skin, cartilage, skeletal muscle, synovium, peripheral
blood, dental pulp, umbilical cord, amniotic fluid and placenta
[3,8–10]. The human placenta at term is an alternative, ethically
acceptable, and easily available source of MSCs. Importantly, a
single amnion membrane can yield between 1–46107 stromal
cells, approximately half of what is expected from a term chorion
membrane. This large yield of cells allows for obtaining suitable
amounts of FM-MSCs for cell therapy upon a limited number of
passages, and warrants maximal preservation of the phenotypical
characteristics of the original population of cells. Furthermore fetal
membranes (FM) derived-MSCs are characterized by high
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plasticity [11–13], and are capable of differentiating into both their
natural mesodermal and non mesodermal lineages [14–16],
suggesting similar characteristics as BM-MSCs [17]. Amniotic
membranes contribute to fetal maternal tolerance [18] and their
allogenic transplantation, or transplantation of cells derived from
them, does not induce acute immune rejection even in the absence
of immunosuppression [19–21]. It is not surprising therefore that
FM-MSCs do not elicit allogeneic or xenogeneic immune
responses, and are able to actively suppress lymphocyte prolifer-
ation [22–24]. Accordingly FM-MSCs are considered a promising
source of cells with clinical applications in allogenic transplanta-
tion, as in heterologous peripheric revascularization, and are being
evaluated for their immunomodulatory properties [25–29]. In
addition to the above mentioned therapeutic applications of
MSCs, FM-MSCs are expected to be clinically used as autologous
grafts for fetuses and newborns in peripartum tissue regeneration or
for in utero transplantation in case of genetic disorders without
immunologic rejection by the recipient [30–32], proof of principle
having already been established [33,34]. Lastly, gene transfer in
fetal blood derived MSCs with unperturbed differentiation
potential has been performed [35] and the possible use of FM-
MSCs in antitumor therapeutic strategies has been confirmed
[36,37], paving the way to their potential use in gene therapy
approaches, and large scale production and manufacturing for
clinical trials is being implemented [38–40].
Infections by herpesviruses are a common complication in the
transplant and pregnancy settings. The human Herpesviridae family
is composed of large, enveloped DNA viruses with close structural
similarity and includes the Herpes simplex viruses types 1 and 2
(HSV-1 and 2), Varicella zoster virus (VZV), Epstein Barr virus
(EBV), Human Cytomegalovirus (HCMV), as well as Human
Herpesvirus (HHV) types 6, 7 and 8. All members of the family
replicate in the nucleus of the infected cell after activating a
coordinated cascade of mRNA synthesis, that allows the distinc-
tion of gene transcription into three temporal classes: immediate
early (IE), early (E) and late (L). These viruses all share the ability
to establish latency and reactivate at a later time, and all are
human pathogens. Allogeneic SC transplantation is often compli-
cated by reactivation of herpesviruses, which are also a cause of
morbidity and mortality in the solid organ transplant setting [41].
The presence of selected viruses in MSCs from donor BM has
been investigated [42–44], human fetal BM-MSC support
transcription of HHV-8 LANA/ORF73 messenger (ORF73 from
now on) [44], while adult BM-MSCs have been proved permissive
to HSV-1 and HCMV [43,45], rising concerns regarding their
possible transmission to transplant recipients. Furthermore several
herpesviruses can establish congenital infections: structural fetal
abnormalities can result from intrauterine infection and transmis-
sion of the infection during pregnancy or at the time of delivery
and can result in severe neonatal disease [46].
In the present study we investigated the susceptibility of FM-
MSCs to all members of the human Herpesviridae family. As a
whole, studying FM-MSCs permissivity to herpesviruses is relevant
to: (i) the transplantation field, in that infection of plastic cells used
in regenerative medicine pre- or post-transplant could interfere
with their differentiation process and compromise the engraft-
ment, inducing cytopathology or death of the implanted cells; (ii)
vertical transmission of infections, a setting where mechanisms of
virus spread through the placenta are vastly unexplored, and the
consequences of congenital infection have been poorly character-
ized for most members of the family, especially for what pertains to
stillbirth and post-partum long term sequelae; (iii) gene therapy
and viral vector mediated genetic modification of SCs.
Our results clearly show that FM-MSCs are fully permissive to
infection by HSV-1/2, VZV and CMV. On the other hand,
despite EBV, HHV-6, HHV-7 and HHV-8 being capable of
entering into FM-MSCs, only limited gene expression occurs,
resulting in a nonproductive infection.
Materials And Methods
Antibodies
Surface antigens analysis. Mouse monoclonal antibodies
anti-CD21 (clone LB21) and anti-CD35 (clone E11), were
purchased from Antibodies-Online (Antibodies-Online INC.,
Atlanta, USA); anti-CD19 (clone HD37) was obtained from
DAKO (DAKO, Glostrup, Denmark); anti-CD45 (clone 2D1,
APC), CD11c (S-HCL-3, PE), CD14 (MWP9, PE), CD31 (WM-
59, PE), CD36 (NL07, FITC), CD90 (5E10, FITC), CD59 (P282-
H19, PE), CD184 (12G5, PE) and CD166 (3A6, PE) were
purchased form BD (Becton-Dickinson and Company, New York,
USA); anti-CD106, (1G1b1-PE) was obtained from Southern
Biotechnology (Southern Biotechnology Associates, Birmingham,
USA); anti-HLA-DR (Tu36, FITC), CD105 (SN6, PE), CD44
(MEM 85, FITC), HLA-ABC (Tu149, FITC), CD80 (MEM-233,
PE) and CD29 (MEM101A, PE) were purchased from Caltag
Laboratories (Caltag Laboratories, Bangkok, Thailand), anti-
CD31 (CBL468F, FITC) and CD34 (HPCA-2, Bdis, APC or
PE-Cy7) were obtained from Cymbus Biotechnology (Cymbus
Biotechnology, Chandlers Ford, UK).
Indirect ImmunoFluorescence (IIF). Monoclonal mouse
antibody raised against HSV-1 and HSV-2 gD, clone HDI was a
kind gift from Gabriella Campadelli-Fiume (Bologna, Italy).
HCMV anti-IE clone E13 and anti-pp65, clone 1C3 were
purchased from ARGENE SA (Varilhes, France). Anti-UL44
clone 10D8 was obtained from Virusys (Virusys corp., Taneytown,
USA). Fluorescein (clone sc2010) or Rodhamine (clone sc2092)
conjugated secondary antibodies were purchased from Santa Cruz
(Santa Cruz Biotechnology Inc., Santa Cruz, USA). All antibodies
were diluted in PBS, according to manufacturer’s indications.
Cells
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque density centrifugation of adult buffy coat samples
(S.Orsola-Malpighi University Hospital, Bologna, Italy) and
primary human B lymphocytes were positively selected by
immunomagnetic cell isolation using CD19 Pan B Dynabeads
(Life Technologies, Austin, USA) followed by bead detachment.
Purified B-Cells were mainteined in RPMI 1640 medium
supplemented with 10% FCS. Human embryo lung derived
fibroblasts (HEL; ATCC CCL-137) were cultured in minimal
essential medium (MEM, PAA, Pasching, China), supplemented
with 10% fetal calf serum (FCS) and 100 U/ml penicillin and
100 mg/ml streptomycin (P/S). Human umbilical vascular endo-
thelial cells (HUVECs; ATCC PCS-100-013), were maintained in
endothelial cell growth medium supplemented with 5% FCS and
growth factors (EGM-MV single aliquots, both from BioWhit-
taker, Cambrex Bio Science, Walkersville, MD). Vero (ATCC
CCL-81) and baby hamster kidney (BHK; ATCC CCL-10) cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM, EuroClone, Milan, Italy) supplemented with 5% FCS,
and P/S. T lymphoid J-Jhan [47] and Sup T1 (ATCC CRL-1942)
as well as B lymphoid B95-8 (ECACC 85011419) and BC-3
(ATCC CRL-2277) cell lines were grown in suspension in RPMI
1640 (EuroClone, Milan, Italy) supplemented with 10% FCS.
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FM-MSCs isolation, ex vivo culture and characterization
According to the policy approved by the local Ethical
Committee (S. Orsola-Malpighi University Hospital, Bologna,
Italy), all tissue samples were obtained after informed written
consent. FM-MSCs were isolated as described previously [48,49].
Briefly, term placentas from healthy donor mothers obtained from
caesarean sections were rapidly transferred to the laboratory,
rinsed in Phosphate Buffered Saline (PBS) containing P/S (200 U/
ml penicillin, 200 mg/ml streptomycin) and processed immediate-
ly. Amniotic membrane was separated from chorion through blunt
dissection. Pieces of amniotic membrane were minced and
subjected to 15-min digestion with 0.25% trypsin-EDTA solution.
The supernatant (SN) was discarded and the tissue underwent a
second digestion with 0.25% trypsin-EDTA solution, 10 U/ml
DNAseI and 0.1% collagenase IV solution in DMEM (all from
Sigma-Aldrich, St. Louis, USA). Larger pieces of tissue were
allowed to settle under gravity for 5 min at 37uC, while each SN
was transferred to a fresh tube, neutralized with Fetal Bovine
Serum (FBS, Biochrom, Berlin, Germany), then spun down at
6006g for 10 min. Each pellet was resuspended in 5 ml of
DMEM containing 20% FBS, and P/S. Cells were seeded in
25 cm2 flasks and grown at 37uC in 5% CO2. Non-adherent cells
were removed after one week and the medium (with 10% of FBS)
was subsequently changed every four days. When the culture
reached 90% confluence, cells were passaged using 0.25%
Trypsin-EDTA.
Surface antigens were characterized as described elsewhere
[50]. Briefly, trypsinized cells were resuspended in cell culture
medium (10% FBS), incubated on ice for 10 min, washed with
Dulbecco’s phosphate-buffered saline (PBS, pH 7.2, 10% FBS,
Invitrogen, Carlsbad, USA), and labeled with 1 mg/106 cells
FITC-conjugated antibodies for 40 min at 4uC in the dark. Cells
at the 5th passage number were used for all infection experiments.
Sometimes cells at later passage numbers (up to the 20th) were
used, without any appreciable difference in infectability and virus
yield.
Infection
Target cells were seeded either on 24- or 6-well culture plates at
a cell density of 104 cells/cm2. When required, cells were layered
onto coverslips in 24-well plates, grown until they reached
approximately 80% confluence and infected as described below.
Viruses
An HSV-1 clinical isolate at low passage from our diagnostic
laboratory was used in most experiments. The HSV-1 derived
replication deficient viral vector TOZGFP-HSV1, carrying
deletions in the immediate early genes ICP4, ICP22 and ICP27,
and mediating expression of GFP under the control of the ICP22
promoter was also utilized, as indicated [51]. The low passage
HSV-2 (G) laboratory strain was used in this study. Virus stocks
were prepared and titrated in Vero (HSV-1) and BHK (HSV-2)
cells. Briefly, SNs from infected cells approaching 100%
cytopathic effect (cpe) were collected and subjected to three
rounds of 20 sec sonication with a Bandelin Sonoplus sonicator,
Model HD-2200 with an SH213G probe (Bandelin Electronic
GmbH, Berlin, Germany) allowing a 1 min cooling-off period
between each sonication. Cellular debris were pelleted by
centrifugation at 8006g for 20 min at 4uC, and the SN were
aliquoted and stored at 270uC. Titration was performed by
thawing frozen aliquots, which were sequentially tenfold diluted
and used in triplicate to infect Vero or BHK cells layered onto
coverslips in 24-well plates for 1 h at 37uC, in a 5% CO2
atmosphere. The inoculum was then removed, cells were rinsed
with 1 ml PBS and fed with fresh medium. 6 h post-infection (pi) a
neutralizing antibody was added to the medium in order to avoid
extracellular spread of progeny virions. Plaques were counted
three days pi in wells where the dilution of the viral stock allowed
less than 10 plaques to appear, and the correspondent titer was
calculated. FM-MSCs were infected with virus stocks at a
multiplicity of infection (moi) varying from 1–2.5 plaque forming
units (pfu)/cell. Infection was performed for 1 h at 37uC in a
humidified CO2 incubator, then the inoculum was removed and
fresh medium added.
For VZV, a clinical isolate at low passage from our diagnostic
laboratory was used in all experiments. Virus stocks were prepared
in Vero cells by infection with cell-associated virus at a ratio 1:4,
infected to uninfected cells in 75 cm2 plastic flasks, harvesting
infected cells when cpe was .80% with a cell scraper in their
medium. Cell debris were subjected to three rounds of sonication
as for HSV, except that cell debris were not separated from the
medium after sonication, but were directly aliquoted and stored at
270uC. Rough titrations were performed by infection of Vero
cells with serial dilutions of the frozen stocks in 24-well plates,
overlaying a 0.6% agarose containing culture medium 24 h pi and
counting plaques at three days pi FM-MSCs were infected with
VZV virus stocks at a multiplicity of infection (moi),1 pfu/cell.
Infection was performed for 1 h at 37uC in a humidified CO2
incubator, then fresh medium was substituted to the inoculum.
Sometimes HEL cells were used for titration of virus yielded by
FM-MSCs or HEL infected monolayers, following the procedure
described above.
As far as HCMV is concerned, we used the AD169 laboratory
strain and the low passage endotheliotropic TB40 strain. Viral
stocks of TB40 were prepared in HUVECs, while AD169 was
prepared in HEL. Viral stocks were titrated in HEL as described
elsewhere [50]. FM-MSCs and HEL were infected with HCMV
viral stocks with a moi varying between 0.1 to 2.5 pfu/cell.
Infection was performed for 1 h at 37uC in a humidified CO2
incubator, then fresh medium was substituted to the inoculum.
HHV-6 viral stocks were obtained as previously described [52];
HHV-6 variant A (strain U1102) was grown in the T lymphoid J-
Jhan cell line [53]; HHV-6 variant B (strain CV) was grown in the
Sup T1 cell line [54]. A single inoculum was prepared and used for
all infection experiments to avoid variability in the efficiency of
infection due to differences in inocula. Briefly, cell-free viral
inocula were obtained by pelleting a total of 500 ml of cell cultures
(at a concentration of 16106 cells/ml) infected with HHV-6A or
HHV-6B exhibiting complete cpe. The cells were lysed by 3 cycles
of rapid freezing and thawing followed by sonication (3 cycles of
5 sec at medium power with 10 sec intervals in water bath
sonicator). Cleared cellular content was added to culture
supernatant and virions were collected by centrifugation at
200006g at 4uC. Virus particles were purified by density
centrifugation using Optiprep self-forming gradients (Sentinel,
Milan, Italy) at 5.861046g for 3.5 h at 4uC. Collected virions
were suspended in PBS containing 1% bovine serum albumin,
fractioned in aliquots of 100 ml and stored at 280uC until use.
Prior to use, virus stocks were treated with DNase-I and RNase A,
to eliminate free viral nucleic acids eventually present in the
preparation. HHV-6 viral stocks were quantitated by real time
PCR as already described [55] using primers which amplify both
HHV-6 variants. The standard curve was generated by amplifi-
cation of a plasmid containing the targeted HHV-6 sequences.
The method had a 6-log dynamic range and a sensitivity of 20
copies/ml. FM-MSCs were infected with HHV-6A or B with a
moi of 50 genomes/cell. Infection was performed for 2 h at 37uC
Placenta Mesenchymal Stem Cells and Herpesviruses
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e71412
in a humidified CO2 incubator, then the inoculum was removed
and fresh medium added.
HHV-7 Strain CZ [56] was grown in the Sup T1 cell line. Cell
free viral inoculum was obtained as previously described [54].
Briefly, 1 l of HHV-7 infected cell cultures exhibiting complete
cpe was centrifuged at 9006g, resuspended in 2 ml of FCS
supplemented with RNase (50 mg/ml; Boehringer Ingelheim,
Milan, Italy) and disrupted by four cycles of freezing in liquid
nitrogen and thawing at 37uC. The resulting inoculum was
completely free of living cells, as checked by microscopic
observation and cultivation, and was also analyzed by reverse
transcription PCR (both for b-actin and for a panel of viral
mRNAs) to ensure that RNA was completely absent. 16106 FM-
MSCs were infected with 400 ml of the resulting inoculum.
Infection was performed for 2 h at 37uC in a humidified CO2
incubator, then the inoculum was removed and fresh medium
added.
The B95-8 cell line was used to generate infectious EBV virus.
Cells were propagated in complete RPMI medium at 37uC and an
atmosphere of 5% CO2, and fed 2 times per week, maintaining
cell density between 0.5–1.06106/ml. On day 0, 12-O-tetra-
decanoylphorbol-13-acetate (TPA) was added to a final concen-
tration of 25 ng/ml together with sodium butyrate to a final
concentration of 4 mM. The cells were harvested on day 5. Cells
that were not induced were also harvested on the fifth day. SN
from TPA induced B95-8 cells was used to infect FM-MSCs after
clearance at low speed of cellular debris and subsequent filtration
through a 0.45 mm-size-pore filter to remove any remaining
debris. The same SN was ultracentrifuged at 150,0006g for
90 min in a Beckman SW55 rotor and the resulting SN used to
perform mock infections. Titration of inocula was performed by
determining the number of genomes present in serial dilutions of
the final suspension with a real time PCR, targeting the exon 4/5
of the terminal protein gene with primers EB-1 AACATTGG-
CAGCAGGTAAGC and EB-2 ACTTACCAAGTGTCCA-
TAGGAGC, and producing a 182 pb amplicon [57].
FM-MSCs infection was performed with a moi of 100
genomes/cell at 37uC in a humidified CO2 incubator for 2 h,
then the inoculum was removed and replaced with fresh medium.
Mock infections were performed in the same conditions. Primary
human B lymphocytes were infected or mock infected in the same
conditions in parallel.
BC-3 cells, a KSHV/HHV-8 positive primary effusion
lymphoma (PEL) – derived cell line, were used as a source of
HHV-8 and virus was purified by a modification of the protocol
described by Caselli and co-workers [58]. Cells were propagated in
RPMI supplemented with 20% fetal bovine serum at 37uC and an
atmosphere of 5% CO2, fed every 2–3 days for 3–4 weeks until a
minimal amount of 26108 cells was obtained. Cells were then
treated with TPA at 20 ng/ml (Sigma-Aldrich, St. Louis, USA) for
60 h, subsequently centrifuged and the supernatant was collected.
The cell pellet was lysed by three freeze-thaw cycles, centrifuged to
eliminate cell debris, pooled with the supernatant, filtered through
a 0.45-mm-pore-size filter, and concentrated at 4uC overnight with
7% polyethylene glycol 8000 (Sigma-Aldrich, St. Louis, USA).
The suspension was centrifuged at 1.561046g for 2 h at 4uC and
the pellet was resuspended in a small amount of phosphate-buffer
saline (PBS) and purified through a 25% sucrose cushion
(2.6561046g for 3 h in a Beckman JSW-13-1 rotor). The pellet
was resuspended in PBS and layered onto a 40–70% sucrose
gradient and centrifuged at 2.6561046g for 1 h at 4uC in a
Beckman JSW-13-1 rotor. The visible band was collected, dialyzed
O/N against PBS, aliquoted and then stored at 280uC. Serial
dilutions of this stock suspension were titrated by determining the
number of genomes, with a real time PCR targeting the ORF73
gene, using primers HH8-1 59TTGGGAAAGGATGGAAGACG
and HH8-2 59AGTCCCCAGGACCTTGGTTT, which deter-
mine an amplification product of 346 bp [59]. Infection of FM-
MSCs and HUVECs was performed with a moi of 50 genomes/
cell, at 37uC in a humidified CO2 incubator for 2 h. After that the
inoculum was removed and replaced with fresh medium.
Nucleic Acid Purification
At specific time-points pi cells were harvested by trypsinization,
washed twice in cold sterile PBS, collected by centrifugation at
7006g and stored at 280uC until processed. For nucleic acid
extraction and purification cells were thawed, resuspended in
100 ml of cold PBS and total nucleic acid were extracted with the
NucliSENS easyMAG automatic extractor (bioMérieux sa, Marcy
l’Etoile, France), following the manufacturer’s instructions. Puri-
fied material was used both for DNA and RNA analysis.
Polymerase chain reaction (PCR) for detection of viral
DNA in donor FM-MSCs
2 multiplex PCR assays were performed, HERP-1 for HSV-1
and 2, VZV, EBV and HERP-2 for HCMV, HHV-6, HHV-7 and
HHV-8. Primers included were previously described by others
[57,59,60].
PCR analysis for detection of HHV-6A and B, and HHV-7 in
infected FM-MSCs
To determine which samples harbored viral genomic DNA
sequences, 1 mg of DNA (corresponding to 1.56105 cells) was
analyzed by nested PCR by using primers amplifying the U42
gene both for HHV-6A and B, and HHV-7. All primers were
derived from the published HHV-6 and 7 sequences [61,62]. The
primer sequences as well as the PCR conditions were as previously
described [53,54,63,64].
Reverse Transcription-PCR (RT-PCR) for the detection of
viral transcripts in infected FM-MSC
DNA enzymatic degradation was performed by means of
DNAse I Amplification Grade (Invitrogen, Calrsbad, CA, USA).
RT-PCR was performed with the SuperScriptTM III CellsDirect
cDNA Synthesis System (Invitrogen, Calrsbad, CA,USA), and
specific sequences were PCR amplified in an automated thermal
cycler, using the Perfect Taq Plus amplification kit (5 PRIME
GmbH, Hamburg, Deutschland) according to manufacturer’s
instructions. For detection of EBV, the three splicing form of
EBNA-1 transcript were amplified using the set of oligonucleotides
previously published by Chen and co-workers [65], following their
working condition. BZLF1 first round RT-PCR was performed
using 1 ml of cDNA in 50 ml reaction volume and 1.5 mM MgCl2
final concentration, using oligonucleotides BZLF1-OUT-Fw
59AGCAGACATTGGTGTTCCAC and BZLF1-OUT-Rv
59ACATCTGCTTCAACAGGAGG. Amplification reactions
were carried out incubating samples at 95uC for 2 min then a
35 round cycle constituted by 95uC for 30 sec, 55uC for 30 sec
and 72uC for 30 sec incubations, followed by a final incubation at
72uC for 10 min. BZLF1 nested RT-PCR was performed with the
same amplification condition in combination with primers BZLF1-
IN-Fw 59ACGCACGGAAACCACAAC and BZLF1-IN-Rv
59GCGCAGCCTGTCATTTTCAG. RT-PCR for the detection
of HHV-6A and HHV-6B transcripts was performed as described
elsewhere [53,66], while HHV-7 specific transcripts were analyzed
as described in [54]. In the case of HHV-8, ORF73 transcript was
amplified using oligonucleotides ORF73-OUT-Fw 59GAAGTG-
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GATTACCCTGTTGTTAGC and ORF73-OUT-Rv
59AGTCCCCAGGACCTTGGTTT and 2.5 ml of cDNA as
template. ORF 73 semi-nested PCR was performed using oligos
ORF73-OUT-Fw and ORF73-IN-Rv 59TATCTCAGGCCTTC-
CAGTTT ORF50 transcript was amplified with oligonucleotides
ORF50-OUT-Fw 59GCCCTCTGCCTTTTGGTT and
ORF50-OUT-Rv 59GATGATGCTGACGGTGTG. Semi-nest-
ed PCR was performed with oligonucleotides ORF50-IN-Fw 59
GCAAGGTCACTGGACTGTC and ORF50-OUT-Rv. All am-
plification reactions were carried out in a 50 ml reaction volume,
with 1.5 mM MgCl2 final concentration, using 2.5 ml of DNA as
template. A common amplification protocol was used, with the
following conditions: 95uC for 2 min, 406 (95uC for 30 sec, 60uC
for 30 sec and 72uC for 60 sec), 72uC for 10 min final
amplification.
Fluorescence Microscopy
Cells were processed for IIF analysis essentially as described
previously [67]. Following fixation with paraformaldehyde 4% (w/
v) and subsequent membrane permeation with 0.1% TritonX-100
treatment, cells were incubated with primary antibody for one h at
37uC in a humidified chamber. Three wash steps were
subsequently performed in PBS, five min each at room temper-
ature (RT). A secondary antibody, labeled with a fluorophore and
raised against the species producing the primary antibody, was
then incubated with the cells, in the same conditions as for the
primary antibody. Antibody dilutions varied and were generally in
compliance with manufacturers instructions. When human serum
samples from our serotheque collection were used, dilution was
generally 1:50. Cells were then washed for five min three times in
PBS, and subsequently fixed with paraformaldehyde 4% (w/v).
Sometimes nuclei were stained by incubating with DAPI (1 mg/
mL) for 4 min at RT. Samples were washed with PBS, mounted
on coverslips in PBS/glycerol 50% (v/v), and imaged using a
Nikon Eclipse E600 microscope equipped with a Nikon
DXM1200 digital camera and a Nikon Plan Fluor 406 objective
(Nikon, Tokyo, Japan), essentially as previously [68]. Live cells
grown on Willcodishes (Willcowells, Amsterdam, The Nether-
lands) were infected with TOZGFP-HSV1 [51] and analyzed for
GFP expression using a Nikon Eclipse TE2000-U inverted
microscope equipped with a Nikon DXM1200 digital camera
and a Nikon Plan Fluor 406 objective (Nikon, Tokio, Japan), as
previously [69–71]. Mock infected cells were always processed in
the same conditions and observed as a control.
Results
Herpesvirus genomes are not found in term placenta
derived MSCs from healthy (seropositive) individuals
FM-MSCs obtained from term placentas of 6 donors, were
analyzed for the presence of herpesvirus genomes by means of 3
multiplex PCR assays developed in house, HERP-1 for HSV-1
and 2, and VZV, HERP-2 for HCMV, HHV-6, and HHV-7 and
HERP-3 for EBV and HHV-8 [72]. No traces of any herpesvirus
genome were found in any of the six populations of FM-MSCs
used in this study (data not shown).
Permissivity of FM-MSCs to herpesviruses
To assess the infection efficiency of viral stocks, cell lines
permissive to HHVs infection were infected with the same moi
used for FM-MSCs and time-points were collected.
All RNA samples were analyzed by PCR without retro-
transcription (RT) to check the total absence of DNA contami-
nation. No contaminant DNA was present in any sample (see
figures, RT-). Furthermore the efficiency of RT was monitored by
amplification of the human b-actin cDNA, after a 1:100 dilution.
Alpha herpesviruses
HSV-1 and HSV-2. MSCs originated from bone marrow
have been shown to be permissive to HSV-1 [43], while heparan
sulfate has been suggested as a major determinant for virus entry
in adipose tissue derived MSC [73]. To investigate the degree of
permissivity of FM-MSCs to HSV-1 and HSV-2, monolayers of
FM-MSCs were infected with a clinical isolate of HSV-1, or the
HSV-2 laboratory strain G. When infected cells were observed
under an optical inverted microscope, the typical HSV-induced
cpe became apparent from 16–24 h pi at high moi (1A), whereas
cpe was observable only at later times after infection at low moi.
Furthermore, IIF analysis allowed the specific detection of the L
glycoprotein gD (Fig. 1B). Observation of cells infected at high moi
from 18 h pi allowed the identification of polykaryons (Fig. 1B,
bottom panels), whose formation requires L viral proteins gB, gD,
gH and gL, that can be synthesized only after IE and E transcripts
have been translated and DNA replication has been initiated. To
verify that infectious progeny virus was released in the SN of
infected cells, SNs were collected from infected cells at 2, 18 and
24 h pi and infectious virus was titrated on Vero or BHK cells in
the case of HSV-1 or HSV-2, respectively. Both low and high moi
infections proceeded until complete destruction of FM-MSCs
monolayers. Our results show that infectious progeny virions are
yielded from infected FM-MSCs, reaching titers of up to 107 pfu/
ml (Fig. 1C). In conclusion, FM-MSCs can be regarded as fully
permissive for both HSV-1 and HSV-2 viruses.
Interestingly, when FM-MSCs and control Vero cells were
infected with TOZGFP-HSV1, a replication defective viral vector
developed for gene therapy applications by R. Manservigi and P.
Marconi [51], the GFP transgene was readily detectable in both
cell lines, starting from 20 h pi (Fig. S1).
VZV. VZV genomic DNA has been PCR amplified from BM-
MSCs isolated from two osteoarthritis patients in a sample of 18
patients [74]. However, susceptibility of MSC to VZV in vitro has
never been addressed to date. We assayed the permissivity of FM-
MSCs to VZV by infecting monolayers of FM-MSCs, using HEL
as a positive control, with cell-associated VZV (moi,1). When
infected cells were observed under an inverted optical microscope,
foci of cytopathic effect became clearly visible from 4 days pi both
in HEL and in FM-MSCs (Fig. 2A, left panels). At 6 days pi signs
of cell fusion, a hallmark of VZV infection started to appear
(Fig. 2A, middle panels). The effect was more pronounced in FM-
MSCs, where larger polykaryocytes were observable as compared
to HEL. This was even more evident at 9 days pi when cytopathic
effect was generalized in both cell populations. The production of
infectious progeny virions was assayed by titration of cell debris
obtained by sonication of infected cells (moi,1 pfu/cell) collected
at different time points pi, processed as described in Materials and
Methods, and inoculated on HEL cells. As shown in Fig. 2B,
infectious VZV was obtained from both infected HEL and FM-
MSCs with a peak in the production of infectious progeny at 12
days pi. As shown in Fig. 2B, HEL cells yield 2–3 times more
infectious progeny than FM-MSCs in our experimental condi-
tions. Our results clearly show that FM-MSCs are fully permissive
to VZV.
Beta herpesviruses
HCMV. BM-MSCs have been shown to be susceptible to the
AD169 strain [45] and to the clinical isolate TB40 [43] of HCMV.
Here we similarly tested permissivity of FM-MSCs to both AD169
and TB40 viruses. To this end, we infected FM-MSCs, and HEL
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as positive controls, with both viruses at a moi of <1 pfu/cell. At
this moi, a majority of cells in an infected HEL monolayer will
allow progression of the viral replication cycle. The percentage of
cells hosting a full viral replication cycle in a cell population with
unknown permissivity to HCMV compared to that of a population
of HEL infected in parallel with a comparable inoculum, reflects
the permissivity of the cell type. Cells were fixed at different time
points thereafter. IIF assays were then performed with antisera
directed to specific virus encoded products. In order to determine
if representative members of all temporal classes of viral genes
were expressed in these cells, we analyzed the expression of IE, E,
and L genes at 24–96 h pi in both cell populations. As shown in
Fig. 3A, viral genes of all temporal classes of expression were
expressed both in infected HEL and FM-MSCs. To analyze
permissivity of FM-MSCs at the single cell level, counts were made
of IIF positive cells for each antigen studied, at the indicated time
Figure 1. FM-MSCs are susceptible to HSV-1 and HSV-2 infection. (A) FM-MSCs were either mock infected (left panel) or infected with .1
pfu/cell of the indicated viruses before being analyzed with an inverted optical microscope as described in the Materials and Methods section. The
typical cytopathic effect shown is observed starting 12–18 h pi; (B) FM-MSCs were either mock infected (top panels) or infected with .1 pfu/cell of
the indicated viruses before being fixed and processed for IFF using a mAb directed against the late glycoprotein gD to detect infected cells, and
DAPI to visualize cell nuclei. The bright field (BF) is shown in the left panels, and a merged image of all channels is shown in the right panels.
Formation of typical syncytia in infected cells is evident starting at 18 h pi, as shown in the HSV-2 bottom panels; (C) SNs of infected FM-MSCs were
collected at the indicated times pi and used to reinfect Vero (for HSV-1) or BHK (for HSV-2) cells to quantify infectious virion yields in the extracellular
fluid of FM-MSCs by means of plaque assays as described in the Materials and Methods section.
doi:10.1371/journal.pone.0071412.g001
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points, and expressed as a percentage of the whole population.
When the expression of the major IE gene UL123 was analyzed
upon infection with TB40 from 24 to 96 h pi, 82% of the cell
population was found positive at 24 h, 90% at 48 h, 93% at 72 h
and 95% at 96 h pi. When the expression of the E gene
ORFUL44 was analyzed at 24 h and 48 h pi, 58.5% and 72.6% of
FM-MSCs stained positive respectively, while staining of the
matrix protein expressed by the L gene ORFUL99 at 72 h and
96 h pi resulted in 87% and 96% positivity. When HEL cells were
infected with TB40, or FM-MSCs and HEL were infected with a
comparable inoculum of the AD169, we obtained similar results.
As a whole these data suggest that FM-MSCs are fully permissive
to HCMV, and that a replication cycle takes between 72 and 96 h
to complete when cells are infected at a moi of 1 pfu/cell.
To evaluate the kinetics of replication of HCMV in FM-MSCs
at high moi as compared to HEL cells, and verify that infectious
progeny virions are released by infected FM-MSCs, we infected
both cell populations at a moi of 10 pfu/cell with the TB40 strain.
At this moi, the viral replication cycle is synchronized in all cells of
the monolayer, and in HEL cells at 72 h pi progeny virions will
appear in culture SNs. The medium of infected cell monolayers
was therefore collected after 3 days, centrifuged to eliminate cell
debris and frozen, while cells were fed with fresh medium. SNs
were then collected in the same way with a 3 days time interval
until the monolayers were completely lysed by the virus. A titration
of all collected SNs was then performed on HEL. As shown in
Fig. 3B virus yield in both cell populations reached a peak at 6
days pi and decreased gradually. HEL appeared more resistant to
the virus than FM-MSCs, the latter monolayer being completely
lysed 2–3 days before. This accounts for a 2 logs lower virus yield
at 18 days pi in FM-MSCs compared to HEL cultures. Taken
together these results indicate that FM-MSCs are fully permissive
to HCMV.
HHV-6. FM-MSCs were infected with a cell free inoculum of
HHV-6A(U1102) or HHV-6B(CV). The inocula for the two
viruses were standardized, quantitating viral genomes by real-time
PCR. Infection was performed using moi of 50 viral genomes/cell.
The cultures were analyzed at different times (1, 3, 7, 14, 21 and
28 days pi). Infected cultures had a morphology similar to
uninfected cultures and no cpe was detected (data not shown).
DNA was extracted at all time points and analyzed by single round
PCR and nested PCR for the presence of HHV-6A and HHV-6B
DNA, with a PCR specific for U42. For both variants, viral DNA
was present at all time points, up to 21 days pi after single step
PCR, and up to 28 days pi by nested PCR (Fig. 4A). These results
suggested that the amount of intracellular viral DNA decreased
over time, and therefore real-time quantitation of viral DNA was
carried out. The results show that the amount of intracellular
HHV-6 DNA decreased from approximately 56107 genome
equivalents in 1.56104 cells 24 h pi to 56102 at 28 days pi, and
that both variants exhibited the same behavior (Fig. 4B).
Therefore, it is plausible to postulate that viral DNA persisted in
infected cells with low levels of viral replication.
To determine the replicative state of HHV-6 in infected FM-
MSCs, viral transcription was analyzed by RT-PCR for the
presence IE (U42) and L (U22) viral lytic transcripts. The analysis
included also U94/rep, a latency-associated transcript that is
expressed at low levels also during productive infection [55]. The
sensitivity of PCR reactions was similar for all genes, detecting
consistently 103 target molecules after first round PCR and 10–50
target molecules after nested PCR. Cells infected with HHV-6A
showed the presence of U42 and U22 transcripts by first round
PCR until 14 days pi, and the transcript of U94 was detected till
21 days pi. All three transcripts persisted as long as 28 days pi, as
Figure 2. FM-MSCs are fully permissive to VZV infection. (A) HEL
or FM-MSCs were infected with VZV at a moi,1 pfu/cell, as described in
the Materials and Methods section. At the indicated time pi cells were
analyzed by optical microscopy; (B) To determine if the cytopathic effect
observed in (A) was due to productive VZV infection, infected cells were
harvested at different time points pi along with their SNs, and processed
as described in Materials and Methods to reinfect naive HEL cells.
Infectious virus production was subsequently quantified by means of
plaque counting. Each reported pfu value is referred to 105 infected cells.
doi:10.1371/journal.pone.0071412.g002
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shown by nested PCR (Fig. 4C). These results suggest that HHV-
6A establishes a low level productive infection, characterized by
scarce viral replication and decreasing amounts of viral products
(both DNA and RNA) over time.
In the case of cells infected with HHV-6B, single round PCR
failed to show the presence of viral transcripts, and nested PCR
yielded positive results at all time points only for U42 and U94.
The transcript of U22 was detected only during the first 3 days pi
(Fig. 4D). These results suggest that viral replication compatible
with lytic production took place only for a few days, and that
afterwards HHV-6B infection was restricted to the early phase of
the replication cycle, with persistence of IE transcripts (U42 and
U94), and the absence of late mRNAs (U22).
HHV-7. FM-MSCs were infected with a cell free inoculum of
HHV-7 strain CZ. The cultures were analyzed at different times
(1, 3, 7, 14, 21 and 28 days pi). Infected cultures had a morphology
similar to uninfected cultures and no cytopathic effect was detected
(data not shown). DNA was extracted at all time points and
analyzed by single round PCR, with primers and conditions
specific for U42 of HHV-7. Viral DNA was detected at all time
points, without need for nested amplification (Fig. 5A). No precise
quantitation was performed, however the low intensity of the
amplification bands at 21 and 28 days pi suggests that the amount
of viral DNA decreased over time. Analysis of viral transcripts was
carried out by RT-PCR, in order to monitor expression of U42,
U16/17 and U89/90 mRNAs. All these genes belong to the IE
transcriptional class and are expressed at high levels throughout
viral replication, starting immediately after viral entry [54]. Only
U42 mRNA was detected at all time points, with a faint band after
single step PCR. U16/17 and U89/90 mRNA were not detected,
Figure 3. FM-MSCs are fully permissive to HCMV infection. (A) FM-MSCs cells were infected with HCMV (strain TB40) at a moi of 1 pfu/cell and
fixed at 24 (top panels), 48 (middle panels) or 96 (bottom panels) h pi before being processed for IIF staining of HCMV temporal class representative
antigens. Anti-IE (UL123), -E (UL44) or -L (UL99) specific antibodies were used, as indicated at the left of each row. The bright field (BF), the specific
secondary antibody signal (TRITC) and the cell nuclei (DAPI) are shown, with merged images presented in the right panels; (B) SNs from HEL cells or
from FM-MSCs infected in parallel were harvested at the indicated times pi and used as inocula to determine infectious progeny virion titers via
plaque assays on HEL cells as described in the Materials and Methods section.
doi:10.1371/journal.pone.0071412.g003
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even after nested PCR (Fig. 5B). On the whole, these results show
that HHV-7 infects FM-MSCs cells, and that the virus persists
without a full replication, expressing only some immediate-early
functions [75].
Gamma herpesviruses
EBV. Since EBV infection depends on the receptor CD21,
which is expressed on a limited number of cells, we decided to
investigate whether CD21 is expressed on the surface of FM-
MSCs by FACS analysis. Our results indicate that FM-MSCs
express the EBV receptor (Fig. S2A), and that they are therefore
likely infection targets. To assess the susceptibility of FM-MSCs to
EBV infection, supernatant from a TPA induced B98-5 cell line
was used to infect FM-MSCs and EBV susceptible human B
lymphocytes at a genome/cell ratio of 100. The presence of the
virus did not translate in any morphological change either at the
cell monolayer or at the single cell level as observed by light
microscopy. We set out to investigate if EBV was capable of
penetrating inside FM-MSCs, and to this end we amplified DNA
extraced from infected FM-MSCs and B-lymphocytes with EBV
specific primers. As shown in Fig. 6A genomic DNA was amplified
at up to 28 days pi, with generally very weak signals, while it was
very strongly detected in genomic extracts of infected B-
lymphocytes. Activation of viral transcriptional program was
analyzed in genomic extracts of infected cells by RT-PCR (Fig. 6B).
Our results confirm that EBV is capable of expressing both lytic
(BZLF1) and latency associated (EBNA-1) transcripts during
infection of B lymphocytes [76,77]. By contrast, the same viral
transcripts were undetectable in EBV infected FM-MSCs cell
extracts by both single step and nested RT-PCR. These results
taken together strongly suggest that EBV virions can enter FM-
MSCs but transcription is not allowed while viral DNA persists for
at least 4 weeks pi. Since the cell monolayer is confluent by day 3/
4 pi, it is unlikely that failure to identify traces of viral transcripts or
Figure 4. FM-MSCs are susceptible to HHV-6 A/B variants. FM-MSCs were infected with HHV-6 (variant A and variant B) at a moi of 50
genomes/cell and nucleic acids extracted at the indicated times pi. As positive control an equivalent number of cells permissive to HHV-6 productive
infection (J-Jhan for HHV-6A and SupT1 for HHV-6B) were infected with the same viral stocks used for infecting the stem cells. A) Single step PCR (1st)
and nested PCR (2nd) to detect HHV-6A and B genomes both in FM-MSC cells and J-Jhan and SupT1 cell lines. B) Real-time PCR quantification of HHV-
6A and B genomes. C, D) single step (1st) and nested (2nd) RT-PCR for U42 (Early), U22 (Late) and U94 (latency associated) viral transcripts both in FM-
MSC cells and J-Jhan and SupT1 cell lines infected with HHV-6A (C), or HHV-6B (D) variants. The b-actin RT-positive control is also shown. k- = mock
infected FM-MSCs cells. RT- = PCR amplification of RNA samples without RT.
doi:10.1371/journal.pone.0071412.g004
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genome amplification is due to a dilution effect within a
proliferating population of cells.
HHV-8. It has previously been reported that HHV-8
predominantly infects CD14, CD34 and CD19-expressing cells
[78]. Since CD14 and CD34 expression are not detected in FM-
MSCs [48], we analyzed the surface of FM-MSCs membranes for
the presence of CD19. Cytofluorimetric analysis showed consistent
CD19 expression (Fig. S2B) suggesting that FM-MSC could
represent a potential HHV-8 infection target. Furthermore MSCs
from fetal BM can be infected latently in vitro by HHV-8, and virus
persistence and expression of ORF73 has been documented for
over 9 weeks in those cells [44]. To assess the ability of HHV-8 to
infect FM-MSC, frozen stocks of purified virus were diluted in
serum free medium and added to FM-MSCS at a moi of 50
genomes/cell. Serum free medium was used to establish mock-
infected controls. HUVECs were infected in parallel as positive
controls. Infected FM-MSCs remained unperturbed by the
presence of the virus at all times pi as observed microscopically
whilst infected HUVECs showed typical spindle like aspect, as
previously described [58] (data not shown). The presence of
intracellular and extracellular viral DNA was assessed by PCR
amplification of nucleic acid extracts obtained at days 1 to 28,
from cell monolayer extracts and extracellular fluid. Qualitative
and quantitative analysis were performed on both extracts as
described in Materials and Methods. Viral DNA was readily
detected at all time points tested (Fig. 7A). Analysis of virus-
encoded transcripts was performed on RNA extracted from mock
infected and infected cells from 1 to 28 days pi, and analyzed by
RT-PCR. Expression of ORF50 and ORF73 mRNAs, encoding
for the major transactivator of HHV-8 lytic cycle and for the
latency associated antigen, respectively, was analyzed by RT-PCR
as described in the Materials and Methods section. As shown in
Fig. 7B we did not detect any of the two transcripts at any time
point analyzed from FM-MSCs, while they were both detectable
after infection of HUVECs, accordingly with what previously
reported (data not shown) [58]. When the infection was performed
at high moi (.103 genomes/cell) both ORFUL50 and ORFUL73
generated transcripts were detectable at 3 and 6 days pi, but not at
later time points (Fig. 7C). Taken togheter this data are evocative
of a general albeit short-lived activation of viral promoters in FM-
MSCs, which is not followed by a lytic cascade of genomic
transcription, nor by a detectable latency programme.
When quantitative analysis of virus genome copies content was
implemented in high genome/cell ratio HHV-8 infected FM-
MSC, 1 genome per 25 cells was detected at 3 days pi, 1 genome
per 288 cells was found at 6 days pi, while at 9 days pi the amount
of DNA was under the detection limit. Taken together these results
suggest that HHV-8 is able to penetrate FM-MSCs and PCR
detectable amounts of its genome persist for at least 4 weeks pi,
however limited gene expression is allowed only following high
moi and for less than one week.
Discussion
The present work addresses for the first time the susceptibility of
FM-MSCs to all members of the Herpesviridae family. We show
here that FM-MSCs are susceptible to HSV-1, HSV-2, VZV and
HCMV infection in vitro. While data presented in the present
paper have been obtained using FM-MSCs at the 5th passage,
preliminary data suggest that susceptibility remains unaltered from
the 5th to the 20th passage, confirming the already described
phenotypic stability of these cells throughout extensive expansion.
Our results show that HHV-6A persists in FM-MSCs cells with
low levels of complete viral expression, and therefore with a
potential for production of infectious virus. On the other hand,
HHV-6B and HHV-7 show a more restricted expression, with
persistence of viral DNA and continuous transcription of some
immediate-early genes. Even if late genes are not expressed, it is
not possible to exclude the possibility that these viruses might
undergo full replication under specific conditions of the host cell.
HHV-8 persists for at least 4 weeks in infected FM-MSCs, while
specific transcripts are detectable only upon high moi, but for not
Figure 5. FM-MSCs are not permissive to HHV-7 productive
infection. FM-MSCs (left panels) or SupT1 cells (right panels) were
infected with HHV-7, and nucleic acids were extracted at the indicated
times pi. A) HHV-7 genome single step DNA PCR amplification. B) Single
step (1st) and nested (2nd) RT-PCR to detect HHV-7 transcripts. The b-
actin RT-positive control is also shown. k- = mock infected FM-MSC cells.
RT- = PCR amplification of RNA samples without RT.
doi:10.1371/journal.pone.0071412.g005
Figure 6. FM-MSCs are not permissive to EBV productive
infection. FM-MSCs (left panels) or primary B lymphocytes (right panels)
were infected with EBV, and nucleic acids were extracted at the
indicated times pi. (A) Single step PCR (1st) targeting the EBV genome.
(B) Single step (1st) or nested (2nd) RT-PCR targeting the indicated
transcripts. k- = mock infected FM-MSC cells. RT- = PCR amplification of
RNA samples without RT.
doi:10.1371/journal.pone.0071412.g006
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more than 6 days pi. Our data are consistent with the observation
by Parsons and co-workers that expression of ORF73 is supported
in fetal BM MSC upon infection at high genome/cell ratio [44]. In
our experimental settings duration of ORF73 transcription in
infected cells was shorter, very likely due to lower doses of inocula.
Ethical issues restrict the use of antenatal tissues as a source of
SCs for scientific research and clinical applications. As an
alternative one can rely upon the isolation of SCs from available
fetal tissue samples, as with fetal bioptic or blood sampling and
terminated pregnancies, or term placenta and postnatally retrieved
FM, which yield mainly SCs with mesenchymal cell surface
markers and morphology, MSCs. Amnion and chorion in
particular constitute a valuable source of MSCs [11,13,14].
Herpesviruses are widely spread in the population, with
seroprevalence rates ranging from a minimum of 30% for HCMV
and 60% for HSV-1 in some Western developed Countries, to
over 90% for VZV, HHV-6 and 7 and EBV in the rest of the
world [79].
Our study, showing that FM-MSCs are fully permissive to
members of the Herpesviridae family has implications in three
medical research fields. In regenerative medicine in the first place,
because herpesvirus infections remain a major challenge both in
solid organ and hematopoietic stem cell transplantation, two
settings in which the use of FM-MSCs is being implemented with
growing expectations. In addition, it has been recently reported
that HCMV infection of BM derived MSC hinders their
differentiation abilities, suggesting that infection with certain
herpesviruses could also affect FM-MSCs differentiation potential
[34]. Awareness of the possible contamination of FM-MSCs
isolated with viruses suggests the need for screening isolated cells
for the presence of viral genomes, in order to avoid virus
transmission to transplant recipients. Non-permissive infections in
particular may act as transient viral reservoirs, allowing viral DNA
to be carried on throughout manufacturing practices to the final
cell product used in clinical applications. The possibility of
reactivation events in response to stimuli originated pre- or post-
infusion cannot be ruled out. Furthermore, the infection of
transplanted tissues originated from the expansion of these cells
could have adverse consequences on the outcome of the
engraftment. While the legislation relative to cell products for
therapeutic use is still under development, in Europe and in the
United States, guidelines to good manufacturing practice for
manufacturers of human cells have been issued. The two protocols
‘‘quality of Biotechnology products: viral safety evaluation of
biotechnology products derived from cell lines of human or animal
origin’’, issued by the European Medicine Agency and ‘‘Reflection
paper on stem cell-based medicinal products’’ issued by the
European Committee for Advanced Therapies contain rather
generic recommendations to check cells for contamination by not
better specified human pathogenic viruses. The Tissue Guidance
Document ‘‘Current Good Tissue Practice (CGTP) and Addi-
tional Requirements for Manufacturers of Human Cells, Tissues,
and Cellular and Tissue-Based Products’’, released by the U.S.
Department of Health and Human services recommends testing
cells of human origin for human viruses such as CMV, HIV-1 & 2,
HTLV-1 & 2, EBV, HBV, and HCV. The document specifies that
both master and working cell banks should be subjected to in vitro
and in vivo viral testing. Finally, it states that selected species-
specific testing for adventitious viruses should be performed at the
different stages of manufacturing, including the virus cited above,
and ‘‘other human viral agents’’, as appropriate. Our work
suggests that, in addition to the aforementioned investigations,
donors of FM-MSCs may be considered for serologic screening for
beta and gamma herpesviruses, and cells obtained from herpes-
virus-seropositive donors tested for the presence of corresponding
viruses at the time of banking and at the final step of the
manufacturing process.
A second field of interest is that of vertical transmission of
herpesviruses. Primary infection with HSV has been associated
with spontaneous abortion, premature labor and intrauterine
growth retardation, while primary VZV infection may result in
stillbirth or cause congenital varicella, a syndrome associated with
a significant mortality rate [80]. HCMV is the leading cause of
congenital viral infection and the most common infectious agent of
congenital malformations in developed countries. Viruses and
other difficult to culture organisms have been postulated as the
etiology of a number of obstetric and pediatric conditions of
unknown cause, including stillbirth. Among herpesviruses,
HCMV, HSV, and VZV may cause intrauterine deaths [81].
Infection of FM-MSCs with a member of the Herpesviridae family
could have negative consequences on pregnancy and the fetus
potentially at all times of gestation. MSC from vascularized FMs
could be a first target for replication and dissemination to non-
vascularized FMs and to fetal circulation, both serving as a
reservoir of actively replicating virus, and interfering with the
immune response of resident T cells. Since FM-MSCs have been
shown to enhance fetal repair [82] and couple immunosuppressant
abilities to antimicrobial effector function [83], their depletion by
viral infection could further complicate viral damage to the fetus.
Furthermore herpesviruses are known to cause chromosome
breaks in infected cells [84], that could represent a teratogenic
threat if considering that MSCs traffic between placenta mem-
branes and the fetus [85], especially in very early developmental
stages. Finally, since the placenta is not a barrier to maternal MSC
trafficking, and BM derived MSC have been successfully infected
in vitro with HSV-1 and HCMV, it is conceivable that vertical
Figure 7. FM-MSCs are not permissive to HHV-8 productive
infection. FM-MSCs (left panels) or HUVECs (right panels) were infected
with HHV-8 at low (A, B) or high (C) moi, and nucleic acids were
extracted at the indicated times pi. (A) Single step PCR (1st) targeting
the HHV-8 genome. (B, C) Single step (1st) or nested (2nd) RT-PCR
against the indicated transcripts. k- = mock infected FM-MSC cells. RT-
= PCR amplification of RNA samples without RT.
doi:10.1371/journal.pone.0071412.g007
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transmission could occur via this straightforward route. The
severity of depletion or functional impairment of FM-MSCs
during early gestation could depend upon maternal immune
competence towards HCMV as occurs for cytotrophoblasts [86]
and cause unsuccessful placenta implantation or abnormal
placenta development, resulting in early failure. It is important
to note here that our placenta-derived cells grow in cell culture
conditions. The degree of their representativeness with respect to
the original cell population constituting the stromal layer of
mesenchymal tissue within fetal membranes has been considered
with the intrinsic limitation due to an in vitro model. However,
considering the high amount of MSC that can be isolated from a
tiny area of fetal membranes, the number of passages needed to
characterize the cell population is very limited (3–5), while our
experiments were carried out at passage 5, when we would not
expect major shifts in MSCs biochemical and biological charac-
teristics would have occurred.
Finally our work is relevant to the field of virus mediated gene
therapy applied to SCs. The importance of reprogramming FM-
MSCs functions of interest or orienting their differentiation
potential via gene transfer has been established and has a broad
consensus [87,88].
Because of their propensity to migrate to the sites of injury and
the ability to expand rapidly, FM-MSCs have been considered as
potential gene transfer vehicles to deliver therapeutic genes
[6,7,89]. On the other hand, gene transfer to MSCs can be
achieved by using viral vectors [90–92]. Our data, showing that
infection of FM-MSCs with a replication deficient HSV-1 derived
viral vector mediates GFP transgene expression (Fig. S1), strongly
suggest that genetically modified versions of the herpesviruses may
be used to this end. Using members of the Herpesviridae family for
gene transfer can have several advantages: long-term transgene
expression, repeat vector dosing with a minimal immune response
as a result of the absence of helper viruses during viral packaging,
and simultaneous delivery of large and multiple transgenes [93].
Hybrid HSV/EBV vectors have been used to enhance stability of
transgene expression [94]. Different behavior in terms of genome
stability and differential genome expression in infected cells may
be advantageous to distinct goals as diverse as transient expression
for the induction of differentiation or long term expression of
therapeutic genes.
Supporting Information
Figure S1 FM-MSCs allow transgene expression follow-
ing infection with an HSV-1 based viral vector. FM-MSCs
(upper panels) and Vero (lower panels) cells were infected with the
replication defective viral vector TOZGFP-HSV1 (moi of c. 1),
carrying deletions in three immediate early genes and the GFP
cDNA inserted in the ICP22 locus. The bright field (BF) and the
specific GFP signal (GFP) are shown, with merged images
presented in the right panels.
(TIF)
Figure S2 FM-MSCs express CD21 and CD19 cell
surface proteins. Flow cytometric analysis for the expression
of surface markers CD21 (A) and CD19 (B) in FM-MSCs. Isotype
control peak is shown in black.
(TIF)
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